Journal Advises Calm in Rosiglitazone (Avandia) Uproar
May 24th 2007LONDON -- The editors of The Lancet have cautioned against a rush to judgment in the face of a meta-analysis released Monday that linked the diabetes drug rosiglitazone (Avandia) to a 43% increase in relative risk of myocardial infarction.